CD24 and breast carcinoma: In another clinical trial, advanced breast cancer patients with a GSI MK-0752 treatment plus docetaxel have shown decreased CD44+CD24− and ALDH+ BCSC populations and lower mammosphere formation from their biopsies [204,205] (NCT00106145, NCT00645333).